Table 2.

Open scratch area of U2OS cells treated with putative migration inhibitors. The scratch area at time 0 was set 100%; *** p < 0.001, ** p < 0.01, * p < 0.05; n = number of repetitions. / = cells detached from flask surface

Compound	Concentration (nM)	24 h		48 h		72 h		n
Paclitaxel	Control	41.03 ± 27.83		11.91 ± 14.40		6.09 ± 8.54		6
	10,000	75.67 ± 28.21		70.15 ± 25.93	***	69.49 ± 25.96	***	6
	2000	64.68 ± 20.47		57.75 ± 17.49	***	61.11 ± 17.56	***	6
	400	59.24 ± 16.44		53.24 ± 14.03	***	54.84 ± 17.46	***	6
	80	58.47 ± 13.84		50.23 ± 13.39	***	49.62 ± 14.53	***	6
	16	48.24 ± 12.56		30.49 ± 18.99		26.34 ± 18.47	*	6
	1.6	42.11 ± 27.84		15.68 ± 11.85		4.79 ± 5.37		4
	0.16	42.37 ± 19.51		12.86 ± 7.46		2.89 ± 4.23		3
Vinblastine	Control	43.80 ± 32.59		10.22 ± 13.33		4.35 ± 6.95		4
	5500	72.66 ± 19.76		57.06 ± 15.12	**	70.21 ± 14.25	***	4
	1100	65.92 ± 31.03		58.11 ± 29.74	*	62.65 ± 36.28	*	4
	220	67.60 ± 27.12		60.92 ± 23.69	**	61.14 ± 22.50	**	4
	44	63.52 ± 28.10		55.48 ± 30.19	*	50.97 ± 33.90	*	4
	8.8	69.83 ± 23.52		57.55 ± 30.94	*	55.31 ± 32.09	*	4
	0.88	60.74		25.08		21.46		2
	0.088	30.21		4.30		1.44		2
Colchicine	Control	48.05 ± 24.45		14.30 ± 14.71		7.31 ± 8.94		5
	10,000	68.25 ± 24.54		61.62 ± 34.50	*	63.70 ± 33.17	**	5
	2000	60.03 ± 25.98		47.87 ± 23.46	*	51.51 ± 32.26	*	5
	400	51.41 ± 25.58		45.61 ± 24.09	*	42.70 ± 27.24	*	5
	80	57.52 ± 23.55		52.54 ± 21.60	*	49.97 ± 27.97	*	5
	16	48.62 ± 25.82		37.68 ± 25.16		37.71 ± 26.11	*	5
Compound	Concentration (nM)	24 h		48 h		72 h		n
Podophyllo- toxin	Control	11.66 ± 3.82		2.22 ± 2.36		0.43 ± 0.75		3
	10,000	65.10 ± 4.24	***	76.78 ± 1.37	***	71.37 ± 5.90	***	3
	2000	70.81 ± 28.15	*	66.87 ± 15.93	**	84.08 ± 18.24	**	3
	400	58.66 ± 6.67	***	60.56 ± 2.13	***	63.58 ± 12.85	**	3
	80	66.88 ± 6.17	***	62.97 ± 5.34	***	79.59 ± 14.17	***	3
	16	42.41 ± 1.51	***	34.57 ± 10.57	**	52.73 ± 8.81	***	3
	3.2	10.45 ± 14.19		0		0		3
	0.64	15.70 ± 22.11		0		0		3
Sanguinarine	Control	39.69 ± 13.67		10.73 ± 10.21		4.19 ± 7.67		4
	5000	/		/		/		5
	1000	39.62 ± 12.17		19.70 ± 5.54		13.10 ± 5.47		5
	200	35.96 ± 18.07		18.12 ± 20.85		13.96 ± 20.04		5
	40	29.66 ± 7.64		6.43 ± 7.75		4.37 ± 6.48		5
	8	28.96 ± 15.04		5.07 ± 7.42		2.39 ± 4.84		5
Chelerythrine	Control	39.69 ± 13.67		10.73 ± 10.21		4.19 ± 7.67		4
	12,000	84.35 ± 23.35	*	/		/		5
	2400	34.43 ± 12.35		10.83 ± 14.73		9.34 ± 16.31		5
	480	42.79 ± 13.29		15.89 ± 19.22		10.02 ± 18.69		5
	96	29.69 ± 18.00		11.70 ± 21.10		9.28 ± 19.95		5
	19.5	30.33 ± 17.73		9.07 ± 18.47		7.64 ± 16.94		5
Chelidonine	Control	44.80 ± 16.45		20.16 ± 22.85		14.38 ± 23.73		5
	20,000	57.98 ± 11.72		43.41 ± 24.82		44.06 ± 30.05		5
	4000	44.59 ± 15.78		25.26 ± 23.38		24.46 ± 31.62		5
	800	45.80 ± 17.05		23.94 ± 23.20		21.03 ± 24.67		5
	160	39.21 ± 12.32		15.26 ± 15.19		12.04 ± 16.10		5
	32	30.50 ± 14.01		7.77 ± 11.29		8.22 ± 16.72		5
Homoharring- tonine	Control	3.76 ± 2.83		0.31 ± 0.69		0.26 ± 0.58		3
	8000	78.98 ± 12.39	***	/		/		3
	1600	74.23 ± 20.66	**	68.25 ± 15.17	**	/		3
	320	70.09 ± 6.42	***	72.37 ± 7.95	***	75.60 ± 7.17	***	3
	64	85.25 ± 16.02	***	86.73 ± 12.13	***	83.94 ± 12.26	***	3
	12.8	39.11 ± 7.84	**	28.99 ± 6.44	**	29.76 ± 7.19	**	3
	2.56	13.45 ± 5.53		2.68 ± 3.97		1.95 ± 3.38		3
	0.5	19.08 ± 5.65	*	4.31 ± 1.71		3.95 ± 3.51		3
	0.1	2.18 ± 0.85		0		0		3
Doxorubicin	Control	30.29 ± 15.09		5.06 ± 4.76		0.36 ± 0.62		3
	20,000	86.77 ± 11.70	**	94.33 ± 5.34	***	/		3
	10,000	71.22 ± 4.93	*	76.25 ± 6.40	***	73.47 ± 4.82	***	3
	5000	31.19 ± 2.67		11.32 ± 6.42		7.27 ± 4.59		3
	2500	27.93 ± 17.02		6.43 ± 7.73		0.65 ± 1.12		3
	1250	21.82 ± 17.07		4.76 ± 6.55		0.58 ± 1.01		3

Data are presented as the mean ± SD.